GNE-6776

Cat. No.:	HY-107986
CAS No.:	2009273-71-4
Molecular Formula:	$C_{20}H_{20}N_4O_2$
Molecular Weight:	348.4
Target:	Deubiquitinase
Pathway:	Cell Cycle/DNA Damage
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 100 mg/mL (287.03 mM)

* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions

Solvent / Mass / Concentration	1 mg	5 mg	10 mg
1 mM	2.8703 mL	14.3513 mL	28.7026 mL
5 mM	0.5741 mL	2.8703 mL	5.7405 mL
10 mM	0.2870 mL	1.4351 mL	2.8703 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 2.5 mg/mL (7.18 mM); Clear solution
2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: ≥ 2.5 mg/mL (7.18 mM); Clear solution
3. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: ≥ 2.5 mg/mL (7.18 mM); Clear solution

BIOLOGICAL ACTIVITY

Description	GNE-6776 is a selective and orally bioavailable USP7 inhibitor[1].
IC_{50} & Target	USP7[1]
In Vitro	GNE-6776 significantly inhibits USP7 at 15 μM. GNE-6776 is a highly selective USP7 inhibitor against both recombinant and endogenous cellular deubiquitinases[1].

	MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	GNE-6776 (100 or 200 mg/kg; oral gavage on a once or twice daily schedule; for 10 days) inhibits EOL-1 xenograft growth in mice[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Immunodeficient C.B-17 SCID mice (aged 12-16 weeks) with EOL1 AML xenograft[1]
Dosage:	100 or 200 mg/kg
Administration:	Oral gavage on a once or twice daily schedule; for 10 days
Result:	Significant EOL-1 xenograft growth inhibition.

CUSTOMER VALIDATION

- Theranostics. 2022 May 16;12(9):4348-4373.
- Theranostics. 2020 Jul 23;10(20):9332-9347.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Lorna Kategaya , et al. USP7 Small-Molecule Inhibitors Interfere With Ubiquitin Binding. Nature. 2017 Oct 26;550(7677):534-538.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA